Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Clinical trial NCT05512364 · RECRUITING

Trial details

NCT number: NCT05512364
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

ER-positive Breast Cancer HER2-negative Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer

Start date: 2023-12-15
Primary completion: 2032-11-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.